Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC).
Lung cancer is a leading cause of death worldwide and, although some progress has been made in its treatment, the results remain poor. Better knowledge in tumour biology has allowed us to design anti-target drugs and incorporate them in the treatment of non-small-cell lung cancer (NSCLC). One of the most widely used targeted approaches in this type of tumour has been the inhibition of angiogenesis. Several strategies blocking the VEGF pathway, either at the ligand or recepor level, have been studied and developed. In this review, we present an up-to-date analysis of the current inhibitors of angiogenesis in the treatment of NSCLC.
Carcereny Costa
Enric
E
Servei d'Oncologia Mèdica, Hospital Clínic (ICMHO), Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain. ecarce@clinic.ub.es
Viñolas Segarra
Núria
N
Gascón Vilaplana
Pere
P
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors